Nxera: Building To Become Japan’s Global Biotech Champion

CEO Chris Cargill talks to Scrip about Sosei Heptares’ new identity as Nxera, the ups and downs of being big pharma’s go-to small-molecule drug hunter and its move into commercialization in Japan.

Chris Cargill
Nxera's CEO Chris Cargill • Source: Nxera

First set up in 1990 by former Genentech executive Shinichi Tamura, Sosei, now known as Nxera, was founded with the goal of creating Japan’s “first global biotech champion.”

The need was there

Key Takeaways
  • Nxera is the one of the ‘go-to’ drug discovery firm in small molecules – but is also now a commercial company in Japan as well

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Interviews